Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

547 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S. Ilie SM, et al. Among authors: bergeron a. Breast Cancer. 2023 Nov;30(6):997-1007. doi: 10.1007/s12282-023-01490-1. Epub 2023 Aug 10. Breast Cancer. 2023. PMID: 37561255 Free PMC article.
Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S. Galland L, et al. Among authors: bergeron a. NPJ Breast Cancer. 2022 Mar 4;8(1):28. doi: 10.1038/s41523-022-00395-0. NPJ Breast Cancer. 2022. PMID: 35246547 Free PMC article.
Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.
Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S. Ballot E, et al. Among authors: bergeron a. Breast Cancer Res. 2022 Nov 18;24(1):80. doi: 10.1186/s13058-022-01572-6. Breast Cancer Res. 2022. PMID: 36401316 Free PMC article.
Prognostic stratification ability of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Roussot N, Constantin G, Desmoulins I, Bergeron A, Arnould L, Beltjens F, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Jacinto S, Michel E, Amet A, Coutant C, Costa B, Jouannaud C, Deblock M, Levy C, Ferrero JM, Kerbrat P, Brain E, Mouret-Reynier MA, Coudert B, Bertaut A, Ladoire S. Roussot N, et al. Among authors: bergeron a. Eur J Cancer. 2024 May;202:114037. doi: 10.1016/j.ejca.2024.114037. Epub 2024 Mar 26. Eur J Cancer. 2024. PMID: 38554542 Free article.
Idylla EGFR assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients.
Khalifa E, Chapusot C, Tournier B, Sentis J, Marion E, Remond A, Aubry M, Pioche C, Bergeron A, Primois C, Blanchard L, Millière A, Boucheix M, Léger Y, Bairrao M, Brouste V, Martin L, Soubeyran I. Khalifa E, et al. Among authors: bergeron a. J Clin Pathol. 2023 Oct;76(10):698-704. doi: 10.1136/jcp-2022-208325. Epub 2022 Jul 12. J Clin Pathol. 2023. PMID: 35820776
547 results